Galmed Pharmaceuticals Ltd (GLMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Galmed Pharmaceuticals Ltd (GLMD) has a cash flow conversion efficiency ratio of -0.167x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.13 Million) by net assets ($12.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GLMD company net worth for the company's overall valuation and market capitalisation.
Galmed Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Galmed Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Galmed Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galmed Pharmaceuticals Ltd ranked by their cash flow conversion efficiency. See GLMD debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Adslot Ltd
AU:ADS
|
0.013x |
|
FUTURE METALS NL
F:3R10
|
N/A |
|
Argentum Silver Corp
V:ASL
|
0.017x |
|
Silver Grail Resources Ltd
V:SVG
|
-0.017x |
|
Borneo Olah Sarana Sukses PT
JK:BOSS
|
0.380x |
|
Tsodilo Resources Limited
V:TSD
|
-0.037x |
|
Reliance Global Group Inc
NASDAQ:RELI
|
-0.077x |
|
Wah Fu Education Group Ltd
NASDAQ:WAFU
|
-0.132x |
Annual Cash Flow Conversion Efficiency for Galmed Pharmaceuticals Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of Galmed Pharmaceuticals Ltd from 2012 to 2025. View current stock price of Galmed Pharmaceuticals Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.78 Million | $-6.32 Million | -0.400x | -11.11% |
| 2024-12-31 | $16.33 Million | $-5.88 Million | -0.360x | +18.55% |
| 2023-12-31 | $13.88 Million | $-6.14 Million | -0.442x | +67.92% |
| 2022-12-31 | $13.42 Million | $-18.50 Million | -1.378x | -27.79% |
| 2021-12-31 | $30.50 Million | $-32.89 Million | -1.079x | -81.16% |
| 2020-12-31 | $44.15 Million | $-26.29 Million | -0.595x | -178.42% |
| 2019-12-31 | $69.85 Million | $-14.94 Million | -0.214x | -108.30% |
| 2018-12-31 | $87.89 Million | $-9.02 Million | -0.103x | +86.56% |
| 2017-12-31 | $15.79 Million | $-12.07 Million | -0.764x | +30.24% |
| 2016-12-31 | $11.07 Million | $-12.13 Million | -1.095x | -178.44% |
| 2015-12-31 | $21.55 Million | $-8.47 Million | -0.393x | -33.67% |
| 2014-12-31 | $31.41 Million | $-9.24 Million | -0.294x | -122.74% |
| 2013-12-31 | $-1.95 Million | $-2.52 Million | 1.294x | -16.85% |
| 2012-12-31 | $-1.98 Million | $-3.08 Million | 1.556x | -- |
About Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have… Read more